Jiangsu Coben Pharmaceutical Co., Ltd.

Founded in 2005 and designed and built to GMP standard across a total area of 100,000 square meters, Coben Group is a member of ZJMI Group, a Global Fortune 500 company ranked No. 270 in 2018. Coben specializes in developing and manufacturing APIs and intermediates for various drugs, with main products including Sofosbuvir, Tenofovir, Ticagrelor, Sacubitril, Voriconazole, Isavuconazole and their intermediates.